
    
      For the primary end-point (data collected on Stimulation Day 1), the study will compare
      degarelix 2.5 mg administered in the mid-luteal phase to placebo administered in the
      mid-luteal phase.

      After Stimulation Day 1 the placebo group will be split into two groups: a degarelix 2.5 mg
      follicular group and a ganirelix 0.25 mg group.
    
  